Bifidobacterium bifidum MIMBb75
Selected indexed studies
- Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial. (Lancet Gastroenterol Hepatol, 2020) [PMID:32277872]
- Antibiotics and Probiotics for Irritable Bowel Syndrome. (Drugs, 2023) [PMID:37184752]
- Impact of Bifidobacterium bifidum MIMBb75 on mouse intestinal microorganisms. (FEMS Microbiol Ecol, 2013) [PMID:23551062]
_Worker-drafted node — pending editorial review._
Connections
Bifidobacterium bifidum MIMBb75 helps
Sources
- Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial. (2020) pubmed
- Antibiotics and Probiotics for Irritable Bowel Syndrome. (2023) pubmed
- Impact of Bifidobacterium bifidum MIMBb75 on mouse intestinal microorganisms. (2013) pubmed
- Bifidobacterium bifidum MIMBb75 in irritable bowel syndrome. (2011) pubmed
- Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study. (2011) pubmed
- Study of the adhesion of Bifidobacterium bifidum MIMBb75 to human intestinal cell lines. (2009) pubmed
- Time- and strain-specific downregulation of intestinal EPAS1 via miR-148a by Bifidobacterium bifidum. (2017) pubmed
- Murein lytic enzyme TgaA of Bifidobacterium bifidum MIMBb75 modulates dendritic cell maturation through its cysteine- and histidine-dependent amidohydrolase/peptidase (CHAP) amidase domain. (2014) pubmed
- TgaA, a VirB1-like component belonging to a putative type IV secretion system of Bifidobacterium bifidum MIMBb75. (2014) pubmed
- Effects of Bifidobacterium bifidum in Mice Infected with Citrobacter rodentium. (2019) pubmed